Iodine-131 is by far the most important radionuclide released from the Idaho Chemical Processing Plant, and it was included in a detailed analysis of doses to members of the public. A more refined analysis was also performed for the other 12 radionuclides released from ICPP (Sr-89; Sr-90; Y-91; Zr-95; Nb-95; Ru-103; I-133; Ba-140; Ce-141; Ce-144; Pr-143; and Pu-238).

Estimated I-131 thyroid doses from ICPP were typically less than 4 cSv for individuals who lived at the closest locations downwind from ICPP. Thyroid doses were almost always less than 20 cSv to thyroid. More than 90% the people living around INEL received thyroid doses of less than 0.4 cSv to the thyroid.

Iodine-131 doses from ICPP are lower than doses from other nuclear operations (e.g., Hanford, Washington, or Oak Ridge, Tennessee) and also lower than doses from I-131 fallout from nuclear weapons testing at Nevada Test Site.

Other radionuclides released from ICPP produced effective doses of less than 0.1 cSv, or organ doses of less than 1 cSv. The dose to an individual from all radionuclides combined at the closest downwind location is equivalent to a thyroid dose of 2 cSv from ingestion of I-131.

Dose Assessment Report



Principal authors:
A. Iulian Apostoaei, SENES Oak Ridge, Inc.
Brian A. Thomas, SENES Oak Ridge, Inc.
David C. Kocher, SENES Oak Ridge, Inc.
F. Owen Hoffman, SENES Oak Ridge, Inc.